Jacobson Pharma Corporation Limited (HKG:2633)

Market Cap	2.54B +16.3%
Revenue (ttm)	1.53B -1.9%
Net Income	302.58M +19.5%
EPS	0.15 +17.4%
Shares Out	2.00B
PE Ratio	8.36
Forward PE	8.76
Dividend	0.10 (7.68%)
Ex-Dividend Date	Dec 1, 2025

Volume	180,000
Average Volume	292,402
Open	1.260
Previous Close	1.270
Day's Range	1.260 - 1.270
52-Week Range	0.980 - 1.780
Beta	0.22
RSI	52.82
Earnings Date	Feb 16, 2026

About HKG:2633

Jacobson Pharma Corporation Limited, through its subsidiaries, engages in the research, development, production, sale, and distribution of medicine and drugs in Hong Kong, Mainland China, Macau, Singapore, and internationally. It operates in two segments, Generic Drugs and Branded Healthcare. The company offers generic drugs for various therapeutic categories, including cardiovascular, central nervous, gastrointestinal, respiratory, musculo-skeletal, genito-urinary, anti-infectives, endocrine and metabolic, dermatological, and anti-allergic. It...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2016
• Employees: 1,792
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2633

Financial Performance

In fiscal year 2025, HKG:2633's revenue was 1.58 billion, an increase of 7.43% compared to the previous year's 1.47 billion. Earnings were 300.83 million, an increase of 12.69%.